Condition: Healthy Population · Sponsor: Vedic Lifesciences Pvt. Ltd.
The present study is a randomized, placebo-controlled, parallel study. 250 participants will be screened, and considering a screening failure rate of 20%, approximately 200 participants will be randomized in a ratio of 1:1:1:1:1 to receive either different doses of VL-SE-01 or placebo and will be assigned a unique randomization code. Each group will have at least 30 participants (total 150 completers) after accounting for a dropout/withdrawal rate of 25%. The intervention duration for all the study participants is 180 days.
This description comes directly from the study's public registry record.
Dr Sanjay Vaze, MBBS · 8655670964 · sanjay.v@vediclifesciences.com
Dr. Lalit Pawaskar, M.Pharm, PhD · 7738418890 · lalit.p@vediclifesciences.com
Always discuss trial participation with your own doctor first.
| Shivam Hospital | Dombivali, Maharashtra, India | Recruiting |
| Dhanwantri Hospital | Pune, Maharashtra, India | Recruiting |
| Vedant Multispeciality Hospital | Pune, Maharashtra, India | Recruiting |
| Punawale Hospital | Pune, Maharashtra, India | Recruiting |
| Vishwaraj Hospital | Pune, Maharashtra, India | Recruiting |
| Shree Ashirwad Hospital | Thane, Maharashtra, India | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06473246